A1 Participation

Table A1.1: Participation, by age, 2020–2024

Age group

Number

Crude rate (%)

<25

119,298 

. .

25–29

751,402 

80.5

30–34

713,005 

73.2

35–39

704,681 

76.4

40–44

637,495 

79.9

45–49

579,604 

81.4

50–54

555,852 

82.3

55–59

479,596 

79.1

60–64

449,546 

79.7

65–69

373,480 

78.1

70–74

268,955 

64.3

75+

40,757 

. .

25–74

5,513,616 

77.9

All ages

5,673,671 

. .

Notes 

  1. Number is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025. 
  2. Crude rate is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025 as a percentage of the average ABS estimated resident population for females aged 25–74 in 2020, 2021, 2022, 2023, and 2024, adjusted to exclude the estimated number of females who have had a hysterectomy (using age-specific hysterectomy fractions derived from the AIHW National Hospitals Morbidity Database).

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.2: Participation, by state and territory, participants aged 25–74, 2020–2024

State and territory

Number

Crude rate (%)

AS rate (%)

NSW

1,694,651 

76.7

76.9

Vic

1,451,797 

79.0

79.3

Qld

1,118,625 

78.0

78.2

WA

589,258 

77.9

78.1

SA

380,033 

77.7

78.0

Tas

120,241 

77.8

78.3

ACT

101,963 

79.8

80.5

NT

55,086 

78.8

78.5

Australia

5,513,616 

77.9

78.1

Notes 

  1. Number is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025. 
  2. Crude rate is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025 as a percentage of the average ABS estimated resident population for females aged 25–74 in 2020, 2021, 2022, 2023, and 2024, adjusted to exclude the estimated number of females who have had a hysterectomy (using age-specific hysterectomy fractions derived from the AIHW National Hospitals Morbidity Database).
  3. Age-standardised (AS) rate is the crude rate, age-standardised to the Australian population at 30 June 2001.
  4. State and territory is the state or territory of residence of the participant, which may be different to the state or territory in which the screen took place. Direct comparisons between the states and territories of Australia are not advised, due to the substantial differences that exist between the jurisdictions, including population, area, geographical structure, policies, and other factors.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.3: Participation, by remoteness area, participants aged 25–74, 2020–2024

Remoteness area

Number

Crude rate (%)

AS rate (%)

Major cities

4,066,220

78.3

78.6

Inner regional

940,042

77.7

78.3

Outer regional

410,905

75.0

75.6

Remote

58,815

74.1

74.1

Very remote

35,105

70.1

70.0

Australia

5,513,616 

77.9

78.1

Notes 

  1. Number is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025. 
  2. Crude rate is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025 as a percentage of the average ABS estimated resident population for females aged 25–74 in 2020, 2021, 2022, 2023, and 2024, adjusted to exclude the estimated number of females who have had a hysterectomy (using age-specific hysterectomy fractions derived from the AIHW National Hospitals Morbidity Database).
  3. Age-standardised (AS) rate is the crude rate, age-standardised to the Australian population at 30 June 2001.
  4. Participants were allocated to a remoteness area using their SA2 at the time of their screen (or postcode where SA2 was not available) according to the Australian Statistical Geography Standard (ASGS) for 2021.
  5. Australia does not match the total number of participants across different remoteness areas because some participants were not able to be allocated to a remoteness area.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.4: Participation, by socioeconomic area, participants aged 25–74, 2020–2024

Socioeconomic area

Number

Crude rate (%)

AS rate (%)

1 (most disadvantaged)

949,305

69.8

70.2

2

1,031,706

73.8

74.2

3

1,101,561

77.4

77.6

4

1,174,353

80.3

80.6

5 (least disadvantaged)

1,253,806

87.2

87.2

Australia

5,513,616 

77.9

78.1

Notes 

  1. Number is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025. 
  2. Crude rate is the number of participants who had an HPV test between 1 January 2020 and 30 June 2025 as a percentage of the average ABS estimated resident population for females aged 25–74 in 2020, 2021, 2022, 2023, and 2024, adjusted to exclude the estimated number of females who have had a hysterectomy (using age-specific hysterectomy fractions derived from the AIHW National Hospitals Morbidity Database).
  3. Age-standardised (AS) rate is the crude rate, age-standardised to the Australian population at 30 June 2001.
  4. Participants were allocated to a socioeconomic area using their SA2 at the time of their screen (or postcode where SA2 was not available), according to the Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage for 2021.
  5. Australia does not match the total number of participants across different socioeconomic areas because some participants were not able to be allocated to a socioeconomic area.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.5: Participation, by 5-year period, participants aged 25–74, 2018–2022 to 2020–2024

5-year period

 

Number

Crude rate (%)

AS rate (%)

2018–2022

 

5,562,882

80.8

81.1

2019–2023

 

5,485,448

78.6

78.8

2020–2024

 

5,513,616

77.9

78.1

Notes 

  1. Number is the number of participants who had an HPV test between1 January 2018 and 30 June 2023, 1 January 2021 and 30 June 2024, or 1 January 2020 and 30 June 2025. 
  2. Crude rate is the number of participants who had an HPV test between1 January 2018 and 30 June 2023, 1 January 2021 and 30 June 2024, or 1 January 2020 and 30 June 2025 as a percentage of the average ABS estimated resident population for females aged 25–74 in 2018–2022, 2019–2023, or 2020–2024, adjusted to exclude the estimated number of participants who have had a hysterectomy (using age-specific hysterectomy fractions derived from the AIHW National Hospitals Morbidity Database).
  3. Age-standardised (AS) rate is the crude rate, age-standardised to the Australian population at 30 June 2001.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.6: Number of HPV tests, by year, participants aged 25–74, 2018 to 2024

Year

Number of HPV tests

2018

1,899,698

2019

1,935,323

2020

1,085,787

2021

922,345

2022

882,906

2023

1,588,630

2024

1,777,480

Note: Data are the number of HPV tests performed each year, 2018 to 2024, for participants aged 25–74.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.7: Number of HPV tests, by month, participants aged 25–74, January 2020 to June 2025

Month

2020

2021

2022

2023

2024

June 2025

January

115,525

73,226

60,716

99,722

129,175

130,915

February

127,048

87,021

84,565

135,698

165,116

144,747

March

94,868

92,520

83,918

151,361

153,232

136,481

April

51,752

73,129

58,655

107,889

151,242

113,386

May

77,346

77,715

72,848

154,025

168,389

130,776

June

95,585

80,346

68,605

134,158

136,300

110,970

July

93,686

78,218

65,062

133,339

156,606

. .

August

82,011

73,987

76,491

147,781

155,785

. .

September

90,145

73,399

69,465

131,046

145,512

. .

October

92,352

72,251

77,169

143,308

158,745

. .

November

90,891

78,538

88,062

145,082

148,241

. .

December

74,578

61,995

77,350

105,221

109,137

. .

Note: Data are the number of HPV tests performed each month, January 2020 to June 2025, for participants aged 25–74.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.8: Number of self-collected HPV tests, by year, participants aged 25–74, 2018 to 2024

Year

Number of self-collected HPV tests

2018

1,512

2019

3,528

2020

2,887

2021

4,663

2022

40,135

2023

281,782

2024

535,817

Note: Data are the number of HPV tests that were self-collected each year 2018 to 2024, for participants aged 25–74.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Table A1.9: Reason for HPV test, participants aged 25–74, 2020–2024

Reason for HPV test

Number

Per cent

Primary screening HPV test

4,736,429

67.4

Follow-up HPV test (Repeat HPV test after intermediate risk result)

735,387

10.5

Co-test – test of cure

328,691

4.7

Co-test – investigation of signs or symptoms

673,171

9.6

Co-test – other, as recommended in guidelines

178,364

2.5

Other

365,999

5.2

No HPV test performed or unknown reason

6,382

0.1

Total

7,024,423

100.0

Note: Based on participants who had an HPV test between 1 January 2020 and 30 June 2025. All tests in the period are included.

Source: AIHW analysis of NCSR data (NCSR RDE 11/07/2025).

Previous page
Next page